Sign in

Church & Dwight Co., Inc. CHD

Price 98.6 USD
as of 2026-09-05
51/100
Mixed
Quality60
Growth56
Balance-sheet strength47
Valuation42
Momentum50
Income53

Composite 51/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Valuation ranks 42/100 — a slight mark against it.

Case for

Quality ranks 60/100 — a slight point in its favour. Growth ranks 56/100 — a slight point in its favour. Income ranks 53/100 — a slight point in its favour.

Case against

Valuation ranks 42/100 — a slight mark against it. Balance-sheet strength ranks 47/100 — a slight mark against it.

What the company does Church & Dwight (CHD) sells household, personal care, and specialty products under brands such as ARM & HAMMER, OXICLEAN, TROJAN, and FIRST RESPONSE. Its portfolio spans baking soda-based goods, laundry products, oral care, and animal productivity solutions.

Key financials CHD’s profitability metrics include ROE 17%, ROA 7.9%, gross margin 45.6%, operating margin 18.1%, and net margin 12.0%. Revenue growth is 1.6% while EPS growth is 27.2%. The company maintains a debt/equity ratio of 0.56 and a current ratio of 1.15.

Stock health SIDERAVIA scores show Quality 64.6, Growth 60.7, Strength 46.9, Valuation 31.8, Momentum 52.3, and Income 47.7. Piotroski F-Score is 7/9. The stock has 3m momentum of 6.42% and RSI(14) at 58.80.

Price vs fair value CHD trades at a discount of 2.70% versus the analyst mean target of 105.37. - Analysts highlight margin pressure from commodity costs (Zacks, 2026-08-25) - Competitive dynamics in adjacent categories noted (Zacks, 2026-08-21) - Recent peer stock volatility may temper near-term sentiment (Barrons.com, 2026-08-24)

Looking forward Forward P/E of 26.32 and PEG of 1.28 suggest moderate earnings expectations. Revenue growth remains modest at 1.6%, while EPS growth of 27.2% reflects margin recovery efforts.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.